← All trials
NCT04680949
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 23, 2020
- Primary completion
- Sep 20, 2021
- Completion date
- Dec 20, 2021
- First posted
- Dec 23, 2020
- Last posted
- Dec 28, 2020
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hellenic Institute for the Study of SepsisLead sponsor
- Hellenic Institute for the Study of SepsisStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.